Get started
IMMURON LIMITEDIMMURON LIMITEDIMMURON LIMITED

IMMURON LIMITED

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

IMC trade ideas

$IMRNImmuron stock rockets after funding by U.S. DoD of new research agreement Shares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million shares, compared with the full-day average of about 60,500. The award is aimed at testing the efficacy of a single larger dose regimen of Travelan for the treatment of moderate to severe diarrhea upon challenge with enterotoxigenic Escherichia coli (ETEC). "This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022," said Immuron Chief Executive JErry Kanellos. "The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the US Military as well as the civilian international travelling population." The stock has tumbled 30.1% over the past three months while the iShares Biotechnology ETF IBB, -1.11% has declined 7.2% and the S&P 500 SPX, +0.28% has gained 8.3%.
NASDAQ:IMRNLong
by BADQOMOCAWGOWLD
1
About to breakout !!The Company www.immuron.com.au Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange (ASX), since April 30, 1999 and our ordinary shares trade under the symbol “IMC.”. Immuron completed an initial public offering on the NADAQ Capital Market in June 2017 and our American Depositary Shares and warrants are listed on NASDAQ under the symbols “IMRN” and “IMRNW”, respectively. Each ADS represents 40 of our ordinary shares, no par value. youtu.be Immuron has just released a study of its Travelan tablets by the US Department of Defense, which shows its effectiveness in preventing traveller’s diarrhoea — in each of 180 strains tested. Dr Kanellos describes it appropriately as a “shock and awe” approach, targeting bacteria the likes of salmonella, food poisoning and Shigella – a disease estimated to cause 80 million to 165 million cases of disease worldwide according to the US Center for Disease Control and Prevention. Pipeline www.immuron.com.au The Technicals Looking at the weekly chart here the average volume on this stock since 2008 been roughly 300k shares. Looks like a breakout pattern with avg volume 4 mil.
ASX:IMCLong
by UnknownUnicorn10209036
1
IMC Covid-19 Simple Solution ?themarketherald.com.au Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus The company tested its IMM-124E treatment and has seen antiviral activity against SARS-CoV-2, the virus that causes COVID-19 IMM-124E is used to manufacture the company's over-the-counter gastrointestinal and digestive health immune supplements, dubbed Travelan and Protectyn To further investigate the treatment's effects, Immuron has researched the bovine coronavirus, commonly found in cows, and how it spreads through feces Because of these findings, Immuron is now looking into what significance an oral therapeutic treatment would have in the fight against COVID-19 The company has filed a provisional patent application to protect these findings On the market today, Immuron is up a whopping 145 per cent and is trading for 60 cents per share Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus. The company's IMME-124E drug is used to manufacture Immuron's over-the-counter gastrointestinal and digestive health immune supplements, dubbed Travelan and Protectyn. Now, Immuron says IMME-124E has seen antiviral activity against the COVID-19 virus in laboratory studies. The company tested the product on SARS-CoV-2, which is the virus that causes COVID-19. The studies were conducted by Melbourne-based contract research organisation 360 Biolabs. Interestingly, Immuron decided to test the drug on SARS-CoV-2 due to its knowledge of bovine coronavirus. What is bovine coronavirus? Bovine coronavirus is common in dairy cows and is transmitted by infected feces taken in via the mouth or nose. The virus starts in the small intestine and eventually reaches the large intestine. To prevent newborn calves getting the disease, the pregnant cows are vaccinated to enhance the level of maternal antibodies, which are then transferred to their offspring. Other ways of preventing and treating the coronavirus involve feeding antibodies against the virus. This can be achieved by feeding antibody-rich colostrum from coronavirus vaccinated animals to the calves. "Therefore, the possibility of producing a Hyper-immune Bovine Colostrum to severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) is quite high," the company explained. "However, the prevalence and prognosis of digestive system involvement and gastrointestinal symptoms in patients with COVID-19 remains largely unknown," it added. Does bovine coronavirus change the current COVID-19 research? COVID-19 patients are known to have respiratory problems, however, gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain have also been observed in a growing number of patients with no respiratory symptoms. CEO Dr Jerry Kanellos said in the U.S., the Centres of Disease Control and Prevention recently updated the symptoms of the coronavirus to include diarrhea. "This growing clinical evidence suggests that the Gastrointestinal tract may present another viral target organ," he said. "The virus RNA has been detected in anal swabs of patients even after nasopharyngeal testing has turned negative, and cells in the inner-gut lining express high amounts of the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses to gain entry to cells implying the potential for gastrointestinal infection and a fecal–oral transmission route," he explained. If the fecal-to-oral transmission is an important factor in the pandemic, then an oral therapeutic treatment would have a significant impact. However, at this stage, the research is still inconclusive. Immuron's new discovery can potentially offer a new oral therapeutic approach to target and directly inhibit the virus in the gastrointestinal tract. The company has filed a provisional patent application to protect these findings. On the market today, Immuron is up a whopping 145 per cent and is trading for 60 cents per share at 1:22 pm AEST.
ASX:IMCLong
by RAZORSWINGTRADER
Immuron’s products found to neutralise Covid-19Immuron’s commercially available products found to neutralise COVID-19 during in vitro research smallcaps.com.au Immuron’s commercially available products found to neutralise COVID-19 during in vitro research By Lorna Nicholas - July 21, 2020 Immuron ASX IMC NASDAQ IMRN SARS-CoV-2 COVID-19 antiviral studies Travelan Protectyn Immuron plans to investigate the impact of its Travelan and Protectyn products further in treating COVID-19 induced gastrointestinal symptoms. Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19. IMM-124E is used in Immuron’s over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers’ diarrhea and other gastrointestinal and digestive issues. The products are commercially available, with Travelan currently registered for use across Australia, Canada and the US. Travelan is an orally administered tablet that is used to reduce the likelihood of contracting travellers’ diarrhea. It is a highly purified preparation of immune bovine antibodies, which, when taken with meals bind to the diarrhea causing bacteria and prevent colonisation and the resultant effect. Testing against COVID-19 A Melbourne-based Contract Research Organisation used the coronavirus-02 (SARS-CoV-2), the virus that causes COVID-19, in an in vitro assessment using IMM-124E. The in vitro assessment using SARS-CoV-2 was performed on four production lots of IMM-124E, with susceptibility assessed. According to Immuron, all four production lots of IMM-124E were seen to inhibit the virus at safe concentrations. The study also found that cell viability in the presence of IMM-124E “was greatly enhanced” compared to the placebo. “We know that SARS-CoV-2 causes an influenza-like disease that is primarily thought to infect the lungs with transmission through the respiratory route ranging from mild respiratory symptoms to severe lung injury, multi-organ failure and death,” Immuron chief executive officer Dr Jerry Kanellos said. “Respiratory symptoms have dominated the clinical focus, however, gastrointestinal symptoms such as diarrhea, vomiting and abdominal pain are also observed in a growing subset of patients often presenting with no respiratory symptoms.” Dr Kanellos added that the symptoms were updated recently in the US to include diarrhea and that there was mounting evidence the virus is also targeting the gastrointestinal tract. COVID-19 and gastrointestinal tract Swabs from COVID-19 patients’ anuses have detected the virus in the same patients who’s nasopharyngeal testing has turned negative. “Cells in the inner-gut lining express high amounts of the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses to gain entry to cells, implying the potential for gastrointestinal infection and a fecal-oral transmission route,” Dr Kanellos explained. “If fecal-oral transmission is a significant factor in the pandemic then the consequences of an oral therapeutic would be significant, however the research is still inconclusive.” Dr Kanellos added the preliminary results with IMM-124E warrant further evaluation. The company has also filed a patent regarding its findings. New oral therapeutic in pipeline Today’s news follows Immuron’s announcement yesterday the US Naval Medical Research Center had received FDA guidance regarding a clinical pathway for Immuron’s investigational new drug, which is being developed to treat campylobacteriosis and enterotoxigenic Escherichia coli infections. “This is an important milestone in the development of any new drug for therapeutic evaluation,” Dr Kanellos said. He added it provides a clear roadmap forward for conducting two planned clinical studies in 2021.
NASDAQ:IMRNLong
by RAZORSWINGTRADER
1
NMRC Requests Meeting with FDA for Guidance on two Phase 2 trialUS DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021 One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis The second trial will focus on ETEC infections “We received a formal start work notification and approval at the end of January 2020 from the Henry Jackson Foundation for the Advancement of Military Medicine to commence work on the sub award,” said Dr. Jerry Kanellos, CEO of Immuron Ltd. Immuron currently markets two products: Protectyn, a formulation of hyperimmune bovine colostrum designed to remove harmful bacteria and their toxins from the gut, and Travelan, an over-the-counter immune supplement to reduce the risk of diarrhea and reduce symptoms of minor GI disorders. seekingalpha.com www.globenewswire.com Immuron, which focuses on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, said it has reached a funding agreement with the U.S. Naval Medical Research Center, or NMRC, to develop a combined Campylobacter and enterotoxigenic E. coli-specific anti-microbial preventative for clinical evaluation. The Department of Defense has approved a $3.7 million funding for the purpose. The agreement provides for Immuron and NMRC collaborating on manufacturing and evaluating the new product that offers protection against travelers' diarrhea caused by Campylobacter and ETEC pathogens. What Next: Immuron said the collaboration will evaluate protective efficacy of the new product using two controlled human infection-model clinical trials, with one focusing on campylobacteriosis, and the second trial on ETEC infections. www.benzinga.com
NASDAQ:IMRN
by AlenCiken
1